20-May-2022 - Evotec SE

Evotec and Almirall enter into a multi-target alliance in medical dermatology

Evotec SE and Almirall S.A. (ALM) announced a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.

The alliance will leverage Evotec’s fully integrated multimodality platform and combine it with Almirall’s leading expertise in Medical Dermatology. Both partners will contribute drug targets in the research process. Leveraging the Company’s end-to-end integrated, AI/ML-driven EVOiR&D platform, Evotec will be responsible for drug discovery and pre-clinical development. Almirall will lead the clinical development and marketing.

Under the agreement, Evotec receives an undisclosed upfront payment, research payments, as well as success-based milestones of potentially up to € 230 m per programme and royalties on net sales in the high single-digit percentage range.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are very happy to enter this collaboration with Almirall, one of the leaders in the field of Medical Dermatology. The collaboration has the potential to deliver superior first-in-class therapeutic options for many patients suffering from severe skin diseases such as atopic dermatitis or basal cell carcinoma. We are looking forward to leveraging the complementary expertise of Evotec and Almirall in order to develop promising new drug candidates.”

Dr Karl Ziegelbauer, Chief Scientific Officer of Almirall, stated: “We are very excited about the strategic alliance with Evotec and believe that combining Almirall’s experience and know-how in Medical Dermatology with Evotec’s integrated drug discovery and preclinical development small molecule platform will enable us to deliver novel solutions for patients suffering from auto-immune skin diseases or common forms of skin cancer.”

Facts, background information, dossiers
More about Evotec
More about Laboratorios Almirall
  • News

    Almirall appoints Peter Guenter as new CEO

    Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the Board of Directors has approved the appointment of Mr. Peter Guenter as CEO of Almirall effective October 1st, 2017. Peter Guenter ... more

    Almirall half-year results 2016

    Almirall, the global pharmaceutical company based in Barcelona, has announced its results for the first half of 2016. Eduardo Sanchiz, CEO, commented: "We have delivered a solid set of results in first half of 2016, boosted by Dermatology which puts us on track to achieve our yearly guidanc ... more

    Almirall closes the acquisition of ThermiGen LLC

    Almirall, S.A. announced the completion of the acquisition of 100% of the share capital of ThermiGen LLC, after all closing conditions have been satisfied. In accordance with the terms of the agreement signed in September 2015, the transaction has been fulfilled and Almirall now owns this m ... more

  • Companies

    Laboratorios Almirall, S.A.

    Almirall is a consolidated international pharmaceutical company where we research, develop and commercialise own R&D and licensed specialities with the aim of improving the health and quality of life of human beings. We devote the maximum human and economic resources to constant research i ... more